Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050595 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL6941060 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL9048730 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL9048615 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL9050107 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL9049272 | 1.00 | SOAT1 (0.54) | SOAT1SMN1; SMN2 | |
| SCHEMBL9049689 | 0.90 | SOAT1 (0.58) | SOAT1 | |
| SCHEMBL9136259 | 0.88 | SMN1; SMN2 (0.52) | SOAT1SMN1; SMN2 | |
| SCHEMBL9049448 | 0.88 | SOAT1 (0.56) | SOAT1SMN1; SMN2 | |
| SCHEMBL9136794 | 0.88 | SMN1; SMN2 (0.59) | SOAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | claimed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | claimed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | claimed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | claimed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | claimed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| US-5475130-A | A thio, sulfonyl, sulfoxidyl or sulfonate acetamide compound as enzyme inhibitor of acyl-coenzyme A cholesterol acyltransferase | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-12 | — | — | US | claimed |
| JP-7196483-A | — | — | None | — | — | JP | disclosed |
| WO-1995014463-A1 | COMPOSITION OF PHARMACEUTICAL PREPARATION IMPROVED IN PERORAL ABSORBABILITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-01 | — | — | WO | disclosed |
| EP-0559898-A1 | ANILIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | SOAT1 149/4885SMN1; SMN2 4282/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | SOAT1 4334/4885SMN1; SMN2 1657/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | SOAT1 1835/4885SMN1; SMN2 3392/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | SOAT1 3925/4885SMN1; SMN2 1775/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | SOAT1 44/4885SMN1; SMN2 2808/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | SOAT1 15/4885SMN1; SMN2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.